Rhabdomyosarcoma

Rhabdomyosarcoma (RMS) is the commonest soft tissue sarcoma (STS) in children. Most cases occur in young children and although the majority are sporadic, RMS can be a manifestation of certain cancer predisposition syndromes. Treatment for RMS involves a multimodality approach including chemotherapy, surgery and radiotherapy with attendant risks of long term treatment related morbidities. Whilst outcomes in localised RMS have improved steadily, those for metastatic and relapsed disease remain poor and there is a pressing need for novel therapeutic approaches. This review outlines the key points related to the diagnosis and management of children with RMS with a focus on current and future practice within the UK and Europe.